RxDoctor Payments DataLook up a doctor →

Lucia Novak, NP

Adult Health · Camp Springs, MDNPI 1851361182

Payments from drug & device makers

$473,310in general payments, 2019–2025

Across 798 payments — averaging $593.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$222K
  • Abbott$138K
  • Sanofi-aventis U.S. LLC$74K
  • Boehringer Ingelheim$18K
  • Medtronic$7K
  • Xeris Pharmaceuticals, Inc.$5K
  • plus $9K from 41 others

What the payments were for

  • Consulting fees$76,64516%
  • Speaking & faculty fees$295,55462%
  • Travel & lodging$79,99817%
  • Food & beverage$21,0964%
  • Education$170%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$473,310 in reported general payments places this provider in the 95th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$25,746
Medicare patients
42
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$97,650
MounjaroTirzepatide54$75,181
JardianceEmpagliflozin34$52,673
Tresiba Flextouch U-200Insulin Degludec15$17,598
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$1,361
Atorvastatin Calcium26$479
Pioglitazone Hcl25$428
Ezetimibe11$391
Metformin Hcl ErMetformin Hcl26$279
Glipizide ErGlipizide11$195
Gabapentin11$192
Levothyroxine Sodium22$186
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide12$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$221,590$97,65051 claims
Lilly USA, LLCMounjaro$1,365$75,18154 claims
Boehringer IngelheimJardiance$18,454$52,67334 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$65$18622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 adult health providers in Maryland.

Other adult health in Camp Springs

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →